Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
复制标题
DOI：
10.1097/jto.0b013e3181b6be57
复制
发表时间：
2009-10
期刊：
影响因子：
--
通讯作者：
Hogendoorn PC
中科院分区：
文献类型：
--
作者：
Giaccone G;Rajan A;Ruijter R;Smit E;van Groeningen C;Hogendoorn PC
胸腺恶性肿瘤是一种罕见的纵隔肿瘤。C-KIT在胸腺癌中高表达，但在胸腺瘤中很少表达。坊间经验表明，甲磺酸伊马替尼在TC中具有活性。这项研究纳入了无法切除的世界卫生组织B3胸腺瘤或TC患者，表现状态为0到2，器官功能良好，且有可测量的疾病。伊马替尼每日口服600 mg。在一个机构招募了七名患者：两名世界卫生组织B3胸腺瘤和五名TC。伊马替尼治疗总体耐受性良好。两名患者病情稳定，五名患者病情恶化。中位生存期为4个月，中位进展时间为2个月。免疫组织化学检测4例标本中有1例表达C-kit。在分析的三个样本中，没有检测到c-kit或PDGFRA基因突变。伊马替尼在这种罕见的肿瘤中没有主要活性。考虑到这项研究中接受治疗的患者数量很少，根据c-kit突变的存在进行选择可能是合理的。
Thymic malignancies are rare tumors of the mediastinum. c-KIT is highly expressed in thymic carcinomas (TC) but infrequently in thymomas. Anecdotal experience suggests activity of imatinib mesylate in TC. Patients with unresectable World Health Organization B3 thymomas or TC, performance status 0 to 2, good organ function, and measurable disease were enrolled in this study. Imatinib was administered at 600 mg PO daily. Seven patients were recruited at one institution: two World Health Organization B3 thymomas and five TC. Imatinib treatment was generally well tolerated. Two patients had stable disease and five progressed. Median survival was 4 months, and median time to progression was 2 months. c-KIT expression was found in one of four samples by immunohistochemistry. No mutations were detected in the c-KIT or PDGFRA genes in three samples analyzed. Imatinib has no major activity in this rare tumor. Given the small number of patients treated in this study, selection based on presence of c-KIT mutations might be warranted.